Arbele is a locally grown pharmaceutical biotech focused on immunotherapy of advanced cancers with high mortality rate (such as liver, stomach, pancreas, esophagus, colon and lung). The company is founded by reputable scientists and senior executives from drug/biotech industry and teamed up with experienced professionals in business, accounting, finance and legal.
Our motto is to excel patient healthcare through innovation and breakthrough. Our mission is to deliver innovative and cost-effective therapeutics to treat diseases of unmet needs. The company philosophy is founded on 3 pillars: breakthrough innovation, health enhancement and social impact. We are committed to reinvest our knowledge and values into the societies for our next generations in the healthcare industry.
For more information: http://www.arbele.org or www.arbele.co
Arbele is focused on antibody-based immunotherapy platforms, including
therapeutic monoclonal antibodies (ADC, BiTE and Bi-specific mAbs) for treatment of advanced gastrointestinal (GI) cancers. For disruptive technology, Arbele scientists in the US are developing new generation of immune T/NK cells for fast-track acceleration of dug candidates into clinical trials in 2018.
Clinical grade Chimeric Antigen Receptor vector for engineered T/NK cells for immunotherapy to treat CDH17-positive cancer
DISCLAIMER OF LIABILITY
The information published on this website is for the public’s reference only. No representation or warranty whatsoever, expressed or implied, is made as to its accuracy, reliability or completeness by HKSTP. Information and any other contents of this website are subject to change without notice.